Metallic Taste (MT) is frequently described during head and neck cancer treatments but very little is known about its etiologies. One hypothesis to explain the MT is the removal of facial nerve inhibition on the glossopharyngeal nerve. Indeed, the decrease of taste afferents mediated by the facial nerve (anterior two-thirds of the tongue) due to cancer or its treatments, would reveal those mediated by the glossopharyngeal nerve (posterior one-third of the tongue) and thus lead to MT perception. The aim of this study was to evaluate the validity of this hypothesis. Selective supraliminar taste tests on the tip and the base of the tongue were regularly performed on 44 patients with head and neck cancers before, during, and after their treatment. Sweet, salty, bitter, sour, and MT were tested. Patients were grouped based on whether they reported experiencing MT or not. 12 patients complained about MT (27.2%), always during the treatment phase. Most of them (83.3%) were treated by surgery and radiotherapy or radiochemotherapy. Supraliminar tastes were altered in every patient, especially during the treatment phase. Test results showed that perceived intensity was significantly reduced in patients reporting MT for salt, sweet and sour. This was observed more on the base of tongue than on the tip of the tongue. MT was significantly linked with mucositis (p=0.027) but with neither candidiasis (p=0.38) nor salivary flow (p=0.63). The hypothesis of removal of facial nerve inhibition on the glossopharyngeal nerve cannot explain MT in head and neck cancer.

The authors have declared no competing interest.

NCT03558789

This study was funded by la Ligue contre le Cancer de la Drome et de l'Ardeche

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Comite de Protection des Personnes Est I, Dijon, France (#2017-A03641-52)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes